Loading…
Loading…
VIVXF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VIVXF and 80,000+ other tickers.
See exactly how VIVXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VIVXF and 80,000+ other tickers.
Avivagen Inc. is a life sciences firm primarily engaged in creating and distributing specialized feed supplements for livestock. These products are designed to bolster animals' immune function and contribute to their enhanced growth and overall productivity. The company's diverse product portfolio includes OxC-beta Livestock, a key additive for animal feeds, alongside canine wellness offerings such as Vivamune and Dr. Tobias dog chews. Furthermore, Avivagen provides the Dr. Tobias Beta blend, formulated to support the human immune system. With a significant international footprint, Avivagen…
Avivagen (OTCMKTS:VIVXF - Get Free Report) and High Tide (NASDAQ: HITI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Analyst Ratings This is a summary of current ratings
Stryker (NYSE: SYK - Get Free Report) and Avivagen (OTCMKTS:VIVXF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Institutional and Insider Ownership 77.1% of Stryker shares are held
Ottawa, Ontario--(Newsfile Corp. - April 24, 2024) - Avivagen Inc. (TSXV: VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance feed intake and support immune function, thereby supporting general health and performance, announced today that is has made a voluntary assignment in bankruptcy for the benefit of its creditors pursuant to section 49 of the Bankruptcy and Insolvency Act (Canada) ("BIA"). BDO Canada Limited has consented to act as Licensed Insolvency Trustee and will administer the estate and realize on the Company's assets in accordance with the BIA.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce a 500kg order for OxC-beta™. The purchase follows a 500kg order in July from the same customer, based in Taiwan, for use within the sow ma.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2023. Third Quarter July 31, 2023, Financial Results The Company's unaudited Financial Statements for the t.